Form 4: Amphastar Pharmaceuticals Executives Receive Stock Options and Restricted Stock Units

Amphastar Pharmaceuticals' CEO Jack Y. Zhang and COO Mary Z. Luo receive stock options and restricted stock units (RSUs) vesting annually starting March 4, 2025.

Summary

• Jack Y. Zhang, CEO and Chief Scientific Officer of Amphastar Pharmaceuticals, and Mary Z. Luo, COO, Chief Scientist, and Chairman, reported changes in their beneficial ownership of the company's stock.
• These changes involve the acquisition of restricted stock units (RSUs) and employee stock options that vest in equal annual installments beginning on March 4, 2025.
• Zhang acquired 64,310 shares represented by RSUs and options for 135,473 shares, while Luo indirectly acquired 27,110 shares represented by RSUs and options for 57,109 shares.
• The exercise price for the stock options is $46.68.
• Following these transactions, Zhang directly owns 2,143,028 shares and indirectly owns 1,131,526 shares, and 6,827,679 shares through Applied Physics and Chemistry Laboratories, Inc.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice that aligns management's interests with shareholders, which is generally viewed favorably.

Positives

• The granting of RSUs and stock options to key executives aligns their interests with those of the shareholders, incentivizing them to improve the company's performance.
• The vesting schedule encourages long-term commitment from the executives.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the pharmaceutical industry.
• Companies like Teva Pharmaceutical Industries and Mylan (now Viatris) also utilize similar compensation strategies to incentivize their executives.
• The vesting schedules and exercise prices are typically benchmarked against industry peers to ensure competitiveness.

Stakeholder Impact

• Shareholders may view the granting of stock options and RSUs positively, as it incentivizes management to increase shareholder value.
• Employees may be motivated by the potential for future stock option grants.

Key Dates